BTIG downgraded TScan Therapeutics (TCRX) to Neutral from Buy.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCRX:
- TScan Therapeutics price target lowered to $6 from $9 at Needham
- TScan Therapeutics’ TSC-101 Gains Buy Rating Amid Promising Trial Results and Strategic Focus on Heme Program
- TScan Therapeutics Shifts Focus to Hematologic Malignancies
- TScan Therapeutics to reduce workforce by 30%
- TScan Therapeutics’ Innovative Cancer Study: A Potential Game-Changer for Solid Tumors